<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow cells of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) frequently undergo <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, though the apoptotic cell ratio decreases when overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> (OL) develops </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, we compared the expression of the inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> protein (IAP) gene family proteins in bone marrow samples from control, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, OL transformed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> --&gt; OL), and de novo <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) subjects by the quantitative real-time RT-PCR method and an immunohistochemical approach </plain></SENT>
<SENT sid="2" pm="."><plain>Overexpression of <z:chebi fb="2" ids="33699">mRNA</z:chebi> for survivin, cIAP1, NAIP and XIAP was significant in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrow cells compared with control samples </plain></SENT>
<SENT sid="3" pm="."><plain>However, the expression of <z:chebi fb="2" ids="33699">mRNA</z:chebi> for survivin, cIAP1 and cIAP2 exhibited a remarkable decrease after the development of OL (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> --&gt; OL) </plain></SENT>
<SENT sid="4" pm="."><plain>By immunohistochemistry, survivin was found to localize to the nucleus of myeloid cells in the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases </plain></SENT>
<SENT sid="5" pm="."><plain>Next, the chronological changes in the expression of IAPs were determined in cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with evolution of OL </plain></SENT>
<SENT sid="6" pm="."><plain>Although the expression of cIAP1 and cIAP2 revealed a sudden or gradual decrease as OL developed, survivin in many cases and XIAP in the majority of cases exhibited a peak of expression before a decline, indicating that these IAPs could be associated with the early events in the development of OL </plain></SENT>
</text></document>